[{"orgOrder":0,"company":"Shandong Lanjin Pharmaceuticals Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Shandong Lanjin Pharmaceuticals Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder","sponsorNew":"Shandong Lanjin Pharmaceuticals Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Shandong Lanjin Pharmaceuticals Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Stichting Hemato-Oncologie voor Volwassenen Nederland","sponsor":"Stichting European Myeloma Network | Gruppo Italiano Malattie EMatologiche dell'Adulto | Deutsche Studiengruppe Multiples Myelom | Nordic Myeloma Study Group | Central European Myeloma Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Stichting Hemato-Oncologie voor Volwassenen Nederland","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Stichting Hemato-Oncologie voor Volwassenen Nederland \/ Stichting European Myeloma Network | Gruppo Italiano Malattie EMatologiche dell'Adulto | Deutsche Studiengruppe Multiples Myelom | Nordic Myeloma Study Group | Central European Myeloma Study Group","highestDevelopmentStatusID":"10","companyTruncated":"Stichting Hemato-Oncologie voor Volwassenen Nederland \/ Stichting European Myeloma Network | Gruppo Italiano Malattie EMatologiche dell'Adulto | Deutsche Studiengruppe Multiples Myelom | Nordic Myeloma Study Group | Central European Myeloma Study Group"},{"orgOrder":0,"company":"Insel Gruppe AG, University Hospital Bern","sponsor":"Mundipharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Insel Gruppe AG, University Hospital Bern","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insel Gruppe AG, University Hospital Bern \/ Mundipharma","highestDevelopmentStatusID":"8","companyTruncated":"Insel Gruppe AG, University Hospital Bern \/ Mundipharma"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncopeptides \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncopeptides \/ Undisclosed"},{"orgOrder":0,"company":"University of Arkansas","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"University of Arkansas","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Arkansas \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"University of Arkansas \/ Amgen Inc"},{"orgOrder":0,"company":"General Oncology, Inc.","sponsor":"Myriad genetics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"General Oncology, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"General Oncology, Inc. \/ Myriad genetics","highestDevelopmentStatusID":"6","companyTruncated":"General Oncology, Inc. \/ Myriad genetics"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Children's Oncology Group \/ National Cancer Institute"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delcath Systems \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"Delcath Systems \/ IQVIA"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delcath Systems \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Delcath Systems \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Spectrum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Spectrum Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Spectrum Pharmaceuticals"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Xi'an Guokang Ruijin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Agreement","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CASI Pharmaceuticals \/ Xi'an Guokang Ruijin Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"CASI Pharmaceuticals \/ Xi'an Guokang Ruijin Pharmaceutical"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delcath Systems \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Delcath Systems \/ Undisclosed"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delcath Systems \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Delcath Systems \/ Undisclosed"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delcath Systems \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Delcath Systems \/ Undisclosed"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delcath Systems \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Delcath Systems \/ Undisclosed"},{"orgOrder":0,"company":"ONCOtherapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ONCOtherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ONCOtherapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"ONCOtherapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delcath Systems \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Delcath Systems \/ Undisclosed"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Public Offering","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Delcath Systems","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Delcath Systems \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Delcath Systems \/ Roth Capital Partners"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Melphalan
Details :
Melphalan is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Details :
Melphalan is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.
Details :
Under the terms of the agreement, China Resources Pharmaceutical Commercial Group International Trading Co., will continue to be the sole distributor for the sale of EVOMELA® (melphalan) for Injection in China.
Details :
Melphalan is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Uveal Melanoma.
Details :
DARZALEX® SC reduces administration time from hours to minutes and demonstrates consistent efficacy with a reduction in administration-related reactions compared to intravenous DARZALEX® (daratumumab).
Details :
Melphalan is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Multiple Myeloma.
Details :
Delcath intends to use the net proceeds of the offering for working capital and general corporate purposes including the continued development of Melphalan/HDS.
Details :
Melphalan is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.
Details :
Melphalan is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Multiple Myeloma.
Details :
Melphalan is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Bile Duct Neoplasms.
Reset All
